Century Therapeutics
Develops iPSC-derived allogeneic cell therapies for autoimmune disease and cancer.
$2.03
After-hours close+0.00 (+0.25%)
At close$2.03(−9.19%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.12 | — | — |
| Aug 2026 | −$0.11 | −$0.17 | −54.5% |
| Aug 2026 | −$0.11 | −$0.17 | −54.5% |
| May 2026 | −$0.15 | −$0.11 | +26.7% |
| Mar 2026 | −$0.28 | −$0.25 | +10.7% |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | −$0.12 | — | — | $1.6M | — | — |
| Aug 13, 2026 | −$0.11 | −$0.17 | −54.5% | $2.2M | — | — |
| Aug 12, 2026 | −$0.11 | −$0.17 | −54.5% | $2.2M | — | — |
| May 13, 2026 | −$0.15 | −$0.11 | +26.7% | $2.9M | — | — |
| Mar 12, 2026 | −$0.28 | −$0.25 | +10.7% | −$62.5K | — | — |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | ||||||
| Nov 13, 2025 | ||||||
| Aug 14, 2025 | ||||||
| May 15, 2025 | ||||||
| Mar 19, 2025 | ||||||
| Nov 5, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 9, 2024 | ||||||
| Mar 14, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Aug 9, 2023 | ||||||
| May 11, 2023 | ||||||
| Mar 16, 2023 | ||||||
| Nov 10, 2022 | ||||||
| Aug 11, 2022 | ||||||
| May 16, 2022 | ||||||
| Mar 17, 2022 | ||||||
| Nov 10, 2021 | ||||||
| Aug 12, 2021 | ||||||
| Jun 21, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||